{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:31:30Z","timestamp":1707525090376},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"DOI":"10.7759\/cureus.41418","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T19:33:06Z","timestamp":1688585586000},"source":"Crossref","is-referenced-by-count":0,"title":["The Safety and Effectiveness of Decapeptide in Patients With Vitiligo: A Real-World Study"],"prefix":"10.7759","author":[{"given":"Aseem","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imran","family":"Majid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hari K","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pravin","family":"Banodkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhulika","family":"Mhatre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhagyashree","family":"Mohod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.12.028","article-title":"Efficacy and safety of tacrolimus 0.1% for the treatment of facial vitiligo: a multicenter randomized, double-blinded, vehicle-controlled study","volume":"141","author":"Seneschal J","year":"2021","unstructured":"Seneschal J, Duplaine A, Maillard H, et al.. Efficacy and safety of tacrolimus 0.1% for the treatment of facial vitiligo: a multicenter randomized, double-blinded, vehicle-controlled study. J Invest Dermatol. 2021, 141:1728-34. 10.1016\/j.jid.2020.12.028","journal-title":"J Invest Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_124_18","article-title":"Clinico-epidemiological profile of patients with vitiligo: a retrospective study from a tertiary care center of North India","volume":"10","author":"Mahajan VK","year":"2019","unstructured":"Mahajan VK, Vashist S, Chauhan PS, Mehta KI, Sharma V, Sharma A. Clinico-epidemiological profile of patients with vitiligo: a retrospective study from a tertiary care center of North India. Indian Dermatol Online J. 2019, 10:38-44. 10.4103\/idoj.IDOJ_124_18","journal-title":"Indian Dermatol Online J"},{"key":"ref3","article-title":"Acetylcholine esterase levels in different clinical types of vitiligo in Baroda, Gujarat","volume":"51","author":"Shajil EM","year":"2006","unstructured":"Shajil EM, Marfatia YS, Begum R. Acetylcholine esterase levels in different clinical types of vitiligo in Baroda, Gujarat. Indian J Dermatol. 2006, 51:289-91.","journal-title":"Indian J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.986918","article-title":"Advances in vitiligo: update on therapeutic targets","volume":"13","author":"Feng Y","year":"2022","unstructured":"Feng Y, Lu Y. Advances in vitiligo: update on therapeutic targets. Front Immunol. 2022, 13:986918. 10.3389\/fimmu.2022.986918","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04368.x","article-title":"Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets","volume":"27","author":"Seif El Nasr H","year":"2013","unstructured":"Seif El Nasr H, Shaker OG, Fawzi MM, El-Hanafi G. Basic fibroblast growth factor and tumour necrosis factor alpha in vitiligo and other hypopigmented disorders: suggestive possible therapeutic targets. J Eur Acad Dermatol Venereol. 2013, 27:103-8. 10.1111\/j.1468-3083.2011.04368.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/iub.1531","article-title":"Basic fibroblast growth factor promotes melanocyte migration via activating PI3K\/Akt-Rac1-FAK-JNK and ERK signaling pathways","volume":"68","author":"Shi H","year":"2016","unstructured":"Shi H, Lin B, Huang Y, et al.. Basic fibroblast growth factor promotes melanocyte migration via activating PI3K\/Akt-Rac1-FAK-JNK and ERK signaling pathways. IUBMB Life. 2016, 68:735-47. 10.1002\/iub.1531","journal-title":"IUBMB Life"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/BF00456389","article-title":"Growth defects of melanocytes in culture from vitiligo subjects are spontaneously corrected in vivo in repigmenting subjects and can be partially corrected by the addition of fibroblast-derived growth factors in vitro","volume":"281","author":"Puri N","year":"1989","unstructured":"Puri N, Mojamdar M, Ramaiah A. Growth defects of melanocytes in culture from vitiligo subjects are spontaneously corrected in vivo in repigmenting subjects and can be partially corrected by the addition of fibroblast-derived growth factors in vitro. Arch Dermatol Res. 1989, 281:178-84. 10.1007\/BF00456389","journal-title":"Arch Dermatol Res"},{"key":"ref8","article-title":"Etiology of vitiligo. A new hypothesis","volume":"69","author":"Ramaiah A","year":"1989","unstructured":"Ramaiah A, Puri N, Mojamdar M. Etiology of vitiligo. A new hypothesis. Acta Derm Venereol. 1989, 69:323-6.","journal-title":"Acta Derm Venereol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.107.4.1611","article-title":"Basic fibroblast growth factor from human keratinocytes is a natural mitogen for melanocytes","volume":"107","author":"Halaban R","year":"1988","unstructured":"Halaban R, Langdon R, Birchall N, et al.. Basic fibroblast growth factor from human keratinocytes is a natural mitogen for melanocytes. J Cell Biol. 1988, 107:1611-9. 10.1083\/jcb.107.4.1611","journal-title":"J Cell Biol"},{"key":"ref10","article-title":"A double blind randomized phase IV clinical trial of basic fibroblast growth factor related deca-peptide in vitiligo","volume":"3","author":"Ramaiah A","year":"2015","unstructured":"Ramaiah A, Kar HK, Garg VK, Bajaj N, Gupta L, Madhava AS. A double blind randomized phase IV clinical trial of basic fibroblast growth factor related deca-peptide in vitiligo. J Pigment Disord. 2015, 3:S3-004.","journal-title":"J Pigment Disord"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.18231\/j.ijced.2020.050","article-title":"Basic fibroblast growth factor (bFGF) related decapeptide 0.1% solution, with tacrolimus 0.1% ointment combination therapy compared with tacrolimus 0.1% ointment monotherapy in the treatment of stable vitiligo: a phase IV, randomized 12 months study","volume":"6","author":"Parsad D","year":"2020","unstructured":"Parsad D, Godse K, Shah B, et al.. Basic fibroblast growth factor (bFGF) related decapeptide 0.1% solution, with tacrolimus 0.1% ointment combination therapy compared with tacrolimus 0.1% ointment monotherapy in the treatment of stable vitiligo: a phase IV, randomized 12 months study. Indian Journal of Clinical and Experimental Dermatology. 2020, 6:249-53. 10.18231\/j.ijced.2020.050","journal-title":"Indian Journal of Clinical and Experimental Dermatology"},{"key":"ref12","unstructured":"Pigmentory agent. (2000). Accessed. May 22, 2023: https:\/\/patents.google.com\/patent\/US6143723A\/en."},{"key":"ref13","article-title":"Comparative study of efficacy and safety of topical active fragment of basic fibroblast growth factor (b FGF) 0.1% solution V\/S betamethasone valerate 0.1% ointment in the treatment of vitiligo patients","volume":"14","author":"Subhashini PK","year":"2015","unstructured":"Subhashini PK, Sankar K, Kambar C, Venkataramana V. Comparative study of efficacy and safety of topical active fragment of basic fibroblast growth factor (b FGF) 0.1% solution V\/S betamethasone valerate 0.1% ointment in the treatment of vitiligo patients. J Dental and Med Sci. 2015, 14:41-7.","journal-title":"J Dental and Med Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.22159\/ijpps.2023v15i4.47383","article-title":"Drug therapy of hypopigmentary disorders of the skin: a hospital-based study","volume":"15","author":"Girish K","year":"2023","unstructured":"Girish K, Gowda N, Jyothi R, Arunnair V. Drug therapy of hypopigmentary disorders of the skin: a hospital-based study. Int J Pharm Pharm Sci. 2023, 15:54-1. 10.22159\/ijpps.2023v15i4.47383","journal-title":"Int J Pharm Pharm Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13109","article-title":"Efficacy and safety of basic fibroblast growth factor (bFGF) related decapeptide solution plus tacrolimus 0.1% ointment versus tacrolimus 0.1% ointment in the treatment of stable vitiligo","volume":"32","author":"Shah B","year":"2019","unstructured":"Shah B, Godse K, Mahajan S, et al.. Efficacy and safety of basic fibroblast growth factor (bFGF) related decapeptide solution plus tacrolimus 0.1% ointment versus tacrolimus 0.1% ointment in the treatment of stable vitiligo. Dermatol Ther. 2019, 32:e13109. 10.1111\/dth.13109","journal-title":"Dermatol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4103\/JCAS.JCAS_33_21","article-title":"Efficacy and safety comparison of basic fibroblast growth factor-related decapeptide 0.1% solution (bFGFrP) plus oral PUVA combination therapy with oral PUVA monotherapy in the treatment of vitiligo","volume":"16","author":"Nayak CS","year":"2023","unstructured":"Nayak CS, Kura MM, Banerjee G, et al.. Efficacy and safety comparison of basic fibroblast growth factor-related decapeptide 0.1% solution (bFGFrP) plus oral PUVA combination therapy with oral PUVA monotherapy in the treatment of vitiligo. J Cutan Aesthet Surg. 2023, 16:28-33. 10.4103\/JCAS.JCAS_33_21","journal-title":"J Cutan Aesthet Surg"},{"key":"ref17","article-title":"A double blind randomized clinical trial on basic fibroblast growth factor related deca-peptide to reduce wrinkles on skin and to treat non sun exposed vitiligo macules","volume":"3","author":"Ramaiah A","year":"2017","unstructured":"Ramaiah A, Madhava AS. A double blind randomized clinical trial on basic fibroblast growth factor related deca-peptide to reduce wrinkles on skin and to treat non sun exposed vitiligo macules. Cosmetol & Oro Facial Surg. 2017, 3:2.","journal-title":"Cosmetol & Oro Facial Surg"},{"key":"ref18","unstructured":"Synergistic combinatorial therapies for the treatment of vitiligo. (2012). Accessed. May 22, 2023: https:\/\/patents.google.com\/patent\/AU2005203228B2\/en."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/165830-the-safety-and-effectiveness-of-decapeptide-in-patients-with-vitiligo-a-real-world-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:02:19Z","timestamp":1707508939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/165830-the-safety-and-effectiveness-of-decapeptide-in-patients-with-vitiligo-a-real-world-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.41418","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,5]]}}}